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Abstract
Introduction 
Previous studies indicate that the incidence of hepatocel-
lular carcinoma in the United States is increasing. These 
reports, however, have contained limited information on 
population groups other than whites and blacks.
Methods
We assessed recent incidence rates and trends for hepa-
tocellular  carcinoma  by  using  newly  available  national 
data from cancer registries participating in the Centers 
for  Disease  Control  and  Prevention’s  National  Program 
of Cancer Registries and the National Cancer Institute’s 
Surveillance,  Epidemiology,  and  End  Results  Program. 
Data  from  registries  in  38  states  and  the  District  of 
Columbia  met  our  criteria;  these  data  covered  83%  of 
the  U.S.  population.  We  computed  age-adjusted  inci-
dence rates and annual percentages of change from 1998 
through 2003.
Results
The  registries  that  we  used  reported  48,048  cases 
of  hepatocellular  carcinoma  (3.4  cases  per  100,000   
population per year) for the study period. Whites account-
ed for three-fourths of cases. The incidence rate for blacks 
was 1.7 times higher than that for whites, and the rate 
for  Asians/Pacific  Islanders  was  4  times  higher  than 
that for whites. Hispanics had 2.5 times the risk of non-
Hispanics. Among Asian/Pacific Islander subgroups, rates 
were highest for people of Vietnamese and Korean origin. 
For  all  races/ethnicities  combined,  the  annual  percent-
ages of change were 4.8% for males and 4.3% for females 
(P < .05). The annual percentage of change was highest 
for people aged 45–59 years (9.0%, P < .05). The annual 
percentage of change for Asians/Pacific Islanders was sta-
tistically unchanged.
Conclusion
We  document  rising  incidence  rates  of  hepatocellular 
carcinoma in the United States during a time when the 
overall incidence of cancer has stabilized. Efforts to col-
lect  representative  etiologic  data  on  new  hepatocellular 
carcinoma cases are needed to enable better characteriza-
tion of trends and to guide the planning and evaluation of 
prevention programs.
Introduction
Approximately 18% of new cases of cancer worldwide 
are attributable to infection. In developing countries, the 
proportion is 26%; in developed countries, 8% (1). Primary 
liver cancer (hepatocellular carcinoma [HCC], cholangio-
carcinoma, hepatoblastoma, and angiosarcoma [2]), which 
is among the leading cancers associated with infection (1), 
ranks sixth among cancers worldwide and is the 18th most 
common malignancy in the United States (3,4). Notable 
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causes of HCC include chronic infection with hepatitis B 
or C virus and alcoholic cirrhosis (5).
HCC accounts for 70% to 85% of primary liver cancer 
in  most  countries.  Rates  are  highest  in  eastern  Asia, 
Southeast  Asia,  and  sub-Saharan  Africa  (6),  with  the 
pronounced  exceptions  of  parts  of  the  Philippines  and 
Thailand,  where  cholangiocarcinoma  secondary  to  liver 
fluke infestation is common (5). In the United States, pri-
mary liver cancer is the fourth most common cancer for 
males of Asian/Pacific Islander origin and the eighth for 
males of Hispanic ethnicity (4); the 5-year survival rate 
is only 8% (7). The incidence rate of HCC in the United 
States  is  reportedly  higher  for  blacks,  Asians/Pacific 
Islanders, and Hispanics than for whites (8-11).
Overall, incidence of HCC doubled in the United States 
from the 1970s through the 1990s (8-11). These findings, 
which are based mainly on data from 9 of the population-
based cancer registries that participate in the National 
Cancer  Institute’s  (NCI’s)  Surveillance,  Epidemiology, 
and End Results (SEER) Program, cover approximately 
10%  of  the  U.S.  population.  Unfortunately,  information 
on incidence for population groups other than whites and 
blacks is limited.
Our  study  assesses  recent  HCC  incidence  rates  and 
trends in the overall U.S. population and among whites, 
blacks, Asians/Pacific Islanders, and Hispanics. We used 
data from the Centers for Disease Control and Prevention’s 
(CDC’s) National Program of Cancer Registries (NPCR) 
and the SEER Program.
Methods
Data sources
Registries  participating  in  the  NPCR  and  the  SEER 
Program are population-based; combined, they cover 100% 
of the U.S. population (4). Both programs use the standard 
data items and codes documented by the North American 
Association of Central Cancer Registries (NAACCR). As 
detailed elsewhere (4), hospitals and other facilities collect 
information from medical records on cancer cases, includ-
ing patient demographics; a small percentage of cases are 
identified from death certificates only.
We analyzed data on cancer incidence by year of diag-
nosis for 1998 through 2003 from registries that met the 
following  data  quality  criteria  for  all  cancer  sites  com-
bined for each study year: 1) case ascertainment was at 
least 90% complete as measured by methods developed by 
NAACCR, 2) 97% or more cases passed a standard set of 
computerized edits, 3) 5% or fewer cases were reported by 
death certificate only or were missing information on the 
patient’s race, and 4) 3% or fewer cases were missing infor-
mation on the patient’s sex or age (4). NPCR and SEER 
registries  augment  identification  of  Hispanic  ethnicity 
with a hierarchical algorithm based on race, birthplace, 
sex, maiden name, and surname (12). Population denomi-
nators for calculating incidence rates were derived from 
the standard 2000 U.S. Census population (4).
NPCR  and  SEER  registries  from  38  states  and  the 
District  of  Columbia  met  our  inclusion  criteria.  These 
registries covered approximately 83% of the overall U.S. 
population  and  84%  of  whites,  74%  of  blacks,  90%  of 
Asians/Pacific  Islanders,  and  91%  of  Hispanics.  NPCR 
data  used  for  this  study  were  reported  to  CDC  as  of 
January 31, 2006. SEER data were reported to NCI as 
of  November  1,  2005.  CDC’s  institutional  review  board 
approved this study.
Variables
To  identify  HCC  cases,  we  used  the  International 
Classification of Diseases for Oncology, Third Edition (ICD-
O-3) site code for liver (C22.0) and histology codes for HCC 
(8170, 8172–8175) (13). We excluded fibrolamellar carcino-
ma (histology code 8171; n = 361), a rare type of liver cancer 
whose etiology, population distribution, and prognosis differ 
from those of HCC (14). We also did not include liver can-
cers with a histology of combined hepatocellular carcinoma 
and cholangiocarcinoma (histology code 8180; n = 584).
We classified the 38 states in our study and the District 
of Columbia according to the U.S. Census Bureau’s defini-
tion of regions (15): 1) Northeast — Connecticut, Maine, 
Massachusetts,  New  Jersey,  New  York,  Pennsylvania, 
Rhode  Island,  and  Vermont;  2)  Midwest  —  Illinois, 
Indiana,  Iowa,  Kansas,  Michigan,  Minnesota,  Missouri, 
Nebraska,  Ohio,  and  Wisconsin;  3)  West  —  Alaska, 
California,  Colorado,  Hawaii,  Idaho,  Montana,  New 
Mexico,  Oregon,  Utah,  and  Washington;  and  4)  South 
— Alabama, Arkansas, Delaware, District of Columbia, 
Florida, Kentucky, Louisiana, Oklahoma, South Carolina, 
Texas, and West Virginia. Study data covered 98% of the 
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We  tabulated  Hispanic  ethnicity  independent  of  race, 
unless otherwise stated. Because work is in progress to 
improve  the  accuracy  of  cancer  rates  among  American 
Indians/Alaska Natives, we do not present data on this 
population separately. These data are, however, included 
in the overall analysis. We classified places of birth outside 
the United States, Puerto Rico, or the U.S. island areas 
(American  Samoa,  the  Commonwealth  of  the  Northern 
Mariana Islands, Guam, and the U.S. Virgin Islands) as 
non-U.S.  birthplaces  (16).  Birthplace  for  patients  diag-
nosed with HCC during the study period was available 
from 13 SEER registries (covering 14% of the U.S. popu-
lation) and from the California statewide NPCR registry 
(covering 12% of the U.S. population). HCC incidence data 
for Asians/Pacific Islanders in California were available 
for the following subgroups: Chinese, Vietnamese, Korean, 
Filipino, and Japanese (17).
Analysis
We present annual and average annual incidence rates 
per 100,000 population. The average annual incidence rate 
is the total number of cases reported from 1998 through 
2003 divided by the sum of the annual denominators. All 
rates except those that are age-specific were age-adjusted 
by the direct method to the standard 2000 U.S. Census 
population on the basis of 19 groups (less than 1 year, 
1–4 years, 5–9 years, 10–14, . . . 85 years and older) (4). 
Age adjustment was performed for results within the age 
strata less than 45, 45–59, 60–74, and 75 years and older.
We computed 95% confidence intervals (CIs) for the age-
adjusted rates by the gamma method (18). We calculated 
rate ratios (RRs) comparing age-adjusted HCC incidence 
rates  (19)  and  used  the  average  annual  percentages  of 
change (APC) to evaluate trends.
To estimate APC, we fit a linear regression line to the 
natural  logarithm  of  the  age-adjusted  annual  rates  (r) 
with year of diagnosis as the predictive variable: ln(r) = 
m(year) + b, where m is the slope of the regression line and 
b is the y-intercept (20).
We calculated APC from the formula APC = 100(em − 
1). A positive APC indicates an increasing trend, and a 
negative APC, a decreasing trend. We assessed statistical 
significance at α < .05, determined by a 2-tailed test. For 
the analysis, we used SEER*Stat, version 6.2.4 (National 
Cancer Institute, Bethesda, Maryland).
Results
From  1998  through  2003,  48,048  HCC  cases  were 
reported to the registries used in our study. In all, 95% of 
the cases were reported from hospital sources, 3% were 
identified solely from autopsy records or death certificates, 
and the remainder from nonhospital sources. The methods 
of diagnosis included microscopic confirmation (79%), radi-
ography without microscopic confirmation (13%), clinical 
diagnosis (4%), and unknown (4%).
The  average  annual  age-adjusted  incidence  rate  of 
HCC was 3.4 per 100,000 population (95% CI, 3.4–3.4) 
(data not shown). Although whites accounted for three-
fourths of HCC cases, they had the lowest rates (Table 
1). The age-adjusted incidence rate of HCC for blacks 
was  approximately  1.7  times  that  for  whites,  and  the 
rate  for  Asians/Pacific  Islanders  was  approximately   
4 times that for whites. The risk of HCC for Hispanics 
was approximately 2.5 times that for non-Hispanics. By 
region, the incidence rate was lowest in the Midwest and 
highest in the West.
Overall,  the  median  age  at  diagnosis  was  64  years 
for males and 71 years for females; this value was low-
est for black males and females. By race/ethnicity, the 
median  ages  among  males  were  66  years  for  whites, 
57  for  blacks,  and  61  for  Asians/Pacific  Islanders  and 
Hispanics. Among females, median ages were 72 years 
for whites, 66 for blacks, 68 for Asians/Pacific Islanders, 
and 70 for Hispanics. Across the age-at-diagnosis groups, 
average  annual  incidence  was  highest  for  both  males 
and females of Asian/Pacific Islander origin (Figure 1). 
After age 40 for Hispanic men and age 45 for Hispanic 
women, age-specific rates were consistently higher than 
those  for  non-Hispanics.  Black  males  had  an  initial 
steep increase in incidence by age that approximated the 
rate  for  Asians/Pacific  Islanders;  however,  the  rate  for 
blacks then leveled off and finally, by approximately age   
75  years,  approached  the  rate  for  whites  (Figure  1). 
Overall, the incidence rate for males was 3.7 times that 
for females (Table 1). The incidence rate for males young-
er than 45 years was 5 times that for females in that age 
group, and the rate for men 45–59 years was 5.6 times 
that of women in that age group.
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Temporal trends
The age-adjusted incidence rate for males rose from 5.0 
in 1998 to 6.2 in 2003, an increase of 24% (age-adjusted 
RR, 1.25; P < .05) (Table 1). For females, incidence in 2003 
was 31% higher than in 1998 (age-adjusted RR, 1.27; P < 
.05). The APC was 4.8% (P < .05) for males and 4.3% (P < 
.05) for females. We found significant increasing trends for 
males in all racial/ethnic subgroups except Asians/Pacific 
Islanders; for females, only whites had a significant increas-
ing trend (Figure 2). In the specific age groups examined, 
the largest increases occurred among patients aged 45–59 
years  at  diagnosis  (APC  9.0%  for  men  and  for  women). 
Among men aged 45–59 years at diagnosis, whites, blacks, 
and Hispanics had significant increases each year, rang-
ing from 9% to 10%; rates for Asian/Pacific Islander males 
were  statistically  unchanged.  The  pattern  by  race  was 
similar for women aged 45–59 years at diagnosis, with the 
exception of the pattern for Hispanics (Figure 2).
The  median  age  at  diagnosis  decreased  from  1998 
through 2003 (males, from 65 to 62 years; females, from 
71 to 70 years), a change that reflects the disproportion-
ate  increases  in  rates  among  middle-aged  people.  Also, 
because rates increased for whites but not for Asians/Pacific 
Islanders, the RR between these 2 groups declined over 
time. For males, the RR between Asians/Pacific Islanders 
and whites was 4.1 (95% CI, 3.8–4.3) for 1998 through 1999 
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Figure 1. Age-Specific Incidence of Hepatocellular Carcinoma, by Patients’ 
Sex and Race/Ethnicity, United States, 1998–2003. 
Data cover 83% of the U.S. population and are from population-based can-
cer registries that participate in the National Program of Cancer Registries 
(NPCR) and the Surveillance, Epidemiology, and End Results (SEER) 
Program and that met study criteria.
Figure 2. Annual Percentage Change (APC) in Incidence of Hepatocellular 
Carcinoma, United States, 1998–2003.  
Data cover 83% of the U.S. population and are from population-based can-
cer registries that participate in the National Program of Cancer Registries 
(NPCR) and the Surveillance, Epidemiology, and End Results (SEER) 
Program and that met study criteria. P < .05 indicates that the APC is sig-
nificantly greater than zero.but dropped for the interval 2002 through 2003 to 3.4 (95% 
CI, 3.3–3.6). For females, comparable RRs were 4.6 (95% 
CI 4.2–5.2) and 4.1 (95% CI, 3.7–4.5). In contrast, the RRs 
between blacks and whites changed very little (data not 
shown in table).
Place of birth
Information  on  place  of  birth  was  available  for  7457 
(78%)  of  the  9615  patients  in  the  SEER  registries.  Of 
these patients, a substantially higher proportion of Asians/
Pacific Islanders (84%) than whites (20%) or blacks (7%) 
was foreign-born (Table 2). Among whites, the proportion 
with non-U.S. birthplaces was higher for Hispanics (42%) 
than for non-Hispanics (12%).
Rates for Asian/Pacific Islander subgroups
Almost  one-half  of  HCC  cases  among  Asians/Pacific 
Islanders in our study were identified from the California 
registry. Among males in this group, age-adjusted inci-
dence rates were highest for the Vietnamese subgroup 
(53.6)  and  lowest  for  the  Japanese  subgroup  (8.4) 
(Table  3).  Among  females,  rates  were  highest  for  the 
Vietnamese (14.3) and Korean (12.3) subgroups and low-
est for the Filipino subgroup (3.7). The proportion of for-
eign-born patients was 95% or higher for all subgroups 
except Japanese (77%).
Discussion
Previous  studies  have  indicated  that  the  incidence  of 
HCC in the United States is higher among males than 
females  and  higher  among  blacks  and  Asians/Pacific 
Islanders  than  whites  (8-11).  We  extend  these  findings 
by  reporting  the  magnitude  of  these  differences  at  the 
national level, and we show that the disparity between 
Asians/Pacific  Islanders  and  whites  decreased  over  the 
6-year study period because rates increased among whites 
but  not  among  Asians/Pacific  Islanders.  We  also  dem-
onstrate  that  HCC  incidence  rates  vary  substantially 
among  U.S.  Asian/Pacific  Islander  subpopulations,  with 
Vietnamese  and  Korean  subgroups  having  the  highest 
rates. Previous studies comparing rates between Asian/
Pacific Islander groups in the United States were based 
on older data or did not differentiate HCC from other liver 
cancers (11,17,21-24).
Hepatitis  B,  a  primary  cause  of  HCC,  is  endemic 
in  Southeast  Asia,  China,  and  other  Asian  countries, 
where  most  infections  are  acquired  in  early  childhood 
through either mother-to-infant transmission or exposure 
to chronically infected household members (25). We found 
that most Asian/Pacific Islander patients with HCC were 
foreign-born and, therefore, most likely to have acquired 
hepatitis B at birth or during early childhood and to have 
been infected for many years. Because measures to pre-
vent perinatal hepatitis B transmission did not become 
available until the 1980s, most U.S.-born Asians/Pacific 
Islanders in our study likely acquired their infections in 
a similar manner (26). We were unable to compute HCC 
incidence rates by birthplace because population denomi-
nators were not available by this variable. However, previ-
ous research reports that rates of liver cancer are higher 
for males born in Asia than for Asian males born in the 
United States, who in turn have rates higher than those 
for white males in the United States (21).
The  racial/ethnic  differences  in  age-specific  incidence 
and trends for HCC that we found most likely reflect dif-
ferences in patterns of chronic hepatitis B and hepatitis 
C as well as host factors and the modulating effects of 
cofactors such as concomitant infections, alcohol intake, 
and diabetes mellitus (5,27,28). The limited etiologic data 
available  suggest  that  hepatitis  B  has  been  the  major 
cause  of  HCC  among  Asians/Pacific  Islanders  and  that 
hepatitis C is the leading cause overall and predominates 
among white, black, and Hispanic patients with HCC in 
the United States (28-30). These data are for select groups 
of patients, however, many of whom received a diagnosis 
of HCC 10 or more years ago. Our ability to ascribe cur-
rent HCC incidence to different etiologies is very limited. 
Surveillance for new hepatitis B and C virus infections, 
which  have  declined  considerably  in  incidence  over  the 
past 2 decades, is of limited relevance because HCC typi-
cally develops after a lag time of 2 to 4 decades after hepa-
titis B or C virus infection (31).
In the United States, national seroprevalence surveys 
have  shown  that  chronic  hepatitis  C  is  approximately 
3 times more common than chronic hepatitis B, but the 
surveys provide limited data by race/ethnicity and region 
(32,33).  Hepatitis  C  has  a  marked  cohort  effect,  with 
prevalence being highest among people born from 1945 
through 1964. Most of these people became infected during 
the 1960s through the 1980s, when incidence was high-
est, and are now at increased risk of developing chronic 
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liver  disease  (32,34,35).  Much  of  the  recent  increase  in 
HCC incidence, and the higher increase in the age group 
45–59 years, most likely reflects the aging of these cohorts. 
Etiologic studies at the individual level are needed to con-
firm the associations with HCC and to extend previous 
findings. For this research, various approaches should be 
explored, including automated capture of available data 
from electronic health records and other data sources and 
linkages between the NPCR and SEER programs and reg-
istries for chronic hepatitis B and C in states where these 
registries are well-established.
Our  study  has  certain  limitations.  First,  we  were 
unable  to  analyze  etiology  because  this  information  is 
not captured by the NPCR and SEER registries. Second, 
information on birthplace from the SEER and California 
registries may not be generalizable because people with 
unknown  birthplaces  are  more  likely  to  be  born  in  the 
United  States  and  because  the  SEER  population  tends 
to be more urban and foreign-born than does the general 
U.S. population (8,36). Third, because the NPCR program 
was established recently, we were unable to estimate long-
term trends in HCC rates at the national level. Fourth, 
the population coverage for the South was approximately 
63%, and the rates for states that were excluded in this 
region or elsewhere may differ from those we report here. 
Fifth, increase in the use of noninvasive methods of diag-
nosis (e.g., radiography) could result in inclusion of more 
false-positive cases over time. We obtained similar results, 
however, when we restricted the analysis to histologically 
confirmed cases (data not shown). Finally, better report-
ing  of  HCC  over  time  might  account  for  the  temporal 
increase. The proportion of all primary liver cancers with 
poorly specified morphology (histology codes 8000–8140) 
decreased by 5 percentage points from 1998 (21%) to 2003 
(16%). Even if such cases are now being coded as HCC, 
however, this change can account for only a small portion 
of the temporal increase, and the variation in trends by 
age group and race suggests that the increases are not an 
artifact of better reporting.
Approaches to preventing HCC include primary preven-
tion of viral hepatitis infections and alcohol-related liver 
disease, secondary prevention of progression to cirrhosis, 
and prevention of cancer in patients with cirrhosis (37). 
A strategy of universal infant vaccination with hepatitis 
B vaccine, the first vaccine developed to prevent cancer, 
had been adopted in 150 (78%) of the 192 World Health 
Organization  member  states  by  2003  (25).  In  Taiwan, 
reductions  in  HCC  incidence  were  demonstrated  after 
implementation  of  infant  vaccination  programs  against 
hepatitis B virus (38). In the United States, the impact 
of  recommendations  from  the  Advisory  Committee  on 
Immunization Practices is reflected in declining hepatitis 
B incidence, which has been striking since the implemen-
tation  of  universal  infant  vaccination  in  1991  (26,39). 
Many  U.S.-born  residents  and  immigrants,  however, 
already  have  chronic  hepatitis  B  or  C  virus  infections, 
so  these  viruses  will  most  likely  persist  for  decades  as 
major causes of HCC. Consequently, support is needed for 
secondary prevention efforts, which rely on identification 
of people with chronic viral hepatitis infection or exces-
sive alcohol consumption to allow for appropriate medical 
management,  including  counseling  and  evaluation  for 
antiviral treatment (40). Furthermore, periodic screening 
with  alpha-fetoprotein  and  ultrasound  has  been  recom-
mended to promote early detection of HCC among selected 
populations with evidence of liver disease, but whether 
this policy results in a reduction in mortality rates has not 
been evaluated (41).
We  documented  rising  HCC  incidence  rates  in  the 
United States during an era in which the overall incidence 
of cancer has stabilized (42). The considerable diversity in 
trends observed among demographic subpopulations most 
likely reflects differences in primary etiology. As others 
have observed, over the next decade HCC cases can be 
expected to continue to increase among people with chron-
ic hepatitis C, but the impact on overall HCC incidence 
rates is difficult to predict because of limited information 
on  etiology  (32,35).  Similarly,  the  impact  on  HCC  inci-
dence rates of immigration of people from countries where 
hepatitis B is endemic will be hard to assess unless more 
detailed demographic and etiologic data are available. To 
better characterize HCC trends and guide the planning 
and  evaluation  of  prevention  programs,  representative 
etiologic data are needed to complement the existing sys-
tem of cancer surveillance in the United States.
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Table 1. Demographic Characteristics of People with Hepatocellular Carcinoma (N = 48,048), United States, 1998–2003a
Demographic 
Characteristics
No. Cases (%)
Age-Adjusted Incidence Rateb 
(95% CI) Rate Ratio (95% CI)
Males Females Males Females Males Females
Overall 35,859 (100) 12,189 (100) 5. (5.-5.7) 1.5 (1.5-1.) NA NA
Age at diagnosis, y
<5 2,159 () 11 (5) 0.5 (0.5-0.5) 0.1 (0.1-0.1) Ref Ref
5-59 12,759 (3) 2,339 (19) 10.0 (9.8-10.2) 1.8 (1.7-1.8) 20.92c (19.98-21.90) 13.01c (11.90-1.2)
0-7 13,291 (37) ,939 (1) 19.7 (19.-20.1) .2 (.0-.) 1.1c (39.33-3.10) 5.97c (2.25-50.08)
≥75 7,50 (21) ,300 (35) 23. (23.1-2.1) 8.1 (7.8-8.3) 9.29c (.98-51.73) 59.83c (5.95-5.23)
Raced
White 2,3 (7) 9,058 (7) .8 (.7-.9) 1.3 (1.3-1.3) Ref Ref
Black ,521 (13) 1, (12) 8. (8.1-8.7) 2.1 (2.0-2.2) 1.75c (1.9-1.81) 1.c (1.55-1.7)
Asian/Pacific 
Islander
,011 (11) 1,5 (12) 17. (17.0-18.2) 5. (5.3-5.9) 3.7c (3.5-3.80) .32c (.08-.58)
Ethnicity
Non-Hispanic 30,570 (85) 10,308 (85) 5.2 (5.2-5.3) 1. (1.-1.) Ref Ref
Hispanic 5,289 (15) 1,881 (15) 11. (11.0-11.7) 3.7 (3.5-3.9) 2.18c (2.12-2.25) 2.2c (2.50-2.7)
Region
Midwest 7,331 (20) 2,585 (21) .3 (.2-.) 1.2 (1.2-1.2) Ref Ref
South 9,90 (2) 3,192 (2) 5. (5.3-5.5) 1.5 (1.-1.5) 1.2c (1.23-1.30) 1.22c (1.1-1.29)
Northeast 9,278 (2) 2,892 (2) .3 (.1-.) 1.5 (1.-1.) 1.c (1.1-1.50) 1.25c (1.19-1.32)
West 9,70 (27) 3,520 (29) .9 (.8-7.0) 2.1 (2.1-2.2) 1.1c (1.5-1.) 1.79c (1.70-1.89)
Diagnosis year
1998 5,032 1,712 5.0 (.9-5.1) 1.3 (1.3-1.) Ref Ref
1999 5,251 1,938 5.1 (5.0-5.3) 1.5 (1.-1.) 1.02 (0.98-1.07) 1.12c (1.05-1.20)
2000 5,751 1,998 5.5 (5.-5.) 1.5 (1.5-1.) 1.10c (1.0-1.1) 1.1c (1.07-1.22)
2001 ,28 2,037 5.9 (5.7-.0) 1.5 (1.5-1.) 1.17c (1.13-1.22) 1.15c (1.08-1.23)
2002 ,59 2,19 .0 (5.9-.2) 1. (1.-1.7) 1.21c (1.1-1.25) 1.23c (1.15-1.31)
2003 ,983 2,310 .2 (.1-.) 1.7 (1.-1.8) 1.25c (1.20-1.30) 1.27c (1.20-1.3)
 
NA indicates not applicable; Ref, referent. 
a Data cover 83% of the U.S. population and are from population-based cancer registries that participate in the National Program of Cancer Registries and 
the Surveillance, Epidemiology, and End Results Program and that met study criteria for data for all years. 
b Rates are per 100,000 population per year, age-adjusted to the standard 2000 U.S. Census population. 
c P < .05. 
d Data not presented for other races.
VOLUME 5: NO. 3
JULY 2008
  www.cdc.gov/pcd/issues/2008/jul/07_0155.htm • Centers for Disease Control and Prevention  9
The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services, 
the Public Health Service, the Centers for Disease Control and Prevention, or the authors’ affiliated institutions. Use of trade names is for identification only 
and does not imply endorsement by any of the groups named above.VOLUME 5: NO. 3
JULY 2008
Table 2. Incidence of Hepatocellular Carcinoma and Birthplaces of Patients, by Race and Hispanic Ethnicity, SEER, 1998–
2003
Race/Ethnicity No. Cases
No. Patients With Known  
Birthplace (%)
Patients With Non-U.S. Birthplace,a %
Males Females All
Overallb 915 757 (78) 3 2 3
White 5779 5 (77) 18 2 20
  Hispanic 153 1179 (75) 3 5 2
  Non-Hispanic 21 32 (77) 11 1 12
Blackc 1110 85 (78)  10 7
Asian/Pacific Islanderc 2578 205 (80) 8 85 8
 
SEER indicates Surveillance, Epidemiology, and End Results Program. 
a Among patients with known birthplace. 
b Data for American Indians/Alaska Natives, although not presented individually, are included in the “overall” category. 
c Fewer than 1% of black and Asian/Pacific Islander patients are of Hispanic ethnicity.
Table 3. Incidence of Hepatocellular Carcinoma and Birthplaces of Patients Among Selected Asian/Pacific Islander 
Subgroups, California, 1998–2003
Asian/Pacific Islander 
Subgroup No. Cases
Age-Adjusted Rate 
(95% CI)a
Patients With Non-U.S. 
Birthplace,b 
%
Males Females All Males Females All
Vietnamese 02 53. (8.2-59.7) 1.3 (11.8-17.3) 32.7 (29.9-35.7) 100 100 100
Korean 372 31.5 (27.-3.3) 12.3 (10.2-1.9) 20.5 (18.-22.9) 97 97 97
Chinese 781 20.8 (19.1-22.) .5 (5.-7.) 13.1 (12.2-1.0) 95 95 95
Filipino 10 1.2 (12.-15.9) 3.7 (3.0-.5) 8.1 (7.3-8.9) 98 9 98
Japanese 20 8. (.7-10.5) .8 (5.-8.3) 7.7 (.7-8.9) 1 87 77
 
a Rates are per 100,000 population per year and age-adjusted to the standard 2000 U.S. Census population. 
b Among patients with known birthplaces (79% of males, 81% of females).
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